ArticlePloS one2025
Nucleated red blood cell count as a novel predictive biomarker for acute kidney injury and prognosis in patients with acute pancreatitis: A retrospective cohort study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesNucleated red blood cells (NRBCs) have been reported to correlate to poor prognosis in critically ill patients. This study aimed to identify the role of NRBC count in early diagnosis of acute kidney injury (AKI) and prediction of poor prognosis in patients with acute pancreatitis (AP).
methodsThis retrospective cohort study enrolled AP patients who were admitted to our hospital from January 1, 2020 to January 1, 2024. Demographic data, NRBC count, laboratory indicators, and outcomes were recorded. Binary logistic regression analysis was used to identify independent biomarkers for AKI diagnosis and prognosis of AP. Receiver operating characteristic (ROC) curves, net reclassification index (NRI) and integrated discrimination improvement (IDI) were used to evaluate the predictive value of NRBC count. Kaplan-Meier curves were generated to compare survival rate between different groups.
resultsA total of 486 patients with AP were included in this study. Patients with NRBCs in their peripheral blood were classified into the NRBC (+) group (n = 190), and those without NRBCs in their peripheral blood were classified into the NRBC (-) group (n = 296). Patients in the NRBC (+) group had a higher AKI incidence (29.5% vs 3.0%, p < 0.001) and poor prognosis rate (12.7% vs 1.0%, p < 0.001) than patients in the NRBC (-) group. Binary logistic regression analysis showed that NRBC count was significantly associated with AKI incidence (OR = 3601.361, p < 0.05) and poor prognosis (OR = 204.434, p < 0.05) in AP patients. Area under the ROC curve (AUC) was 0.830 for NRBC count predicting AKI (cutoff value: 0/L) and 0.867 for NRBC count predicting poor prognosis in AP patients (cutoff value: 0.015 × 109/L). Kaplan-Meier survival analysis demonstrated that patients with NRBC count > 0.015 × 109/L (χ² = 85.09, p < 0.001) exhibited significantly lower survival rates during the 30-day follow-up period. NRBC count offered predictive performance comparable to procalcitonin (PCT) and outperformed C-reactive protein (CRP).
conclusionNRBC count serves as a valuable predictive biomarker for both AKI incidence and poor prognosis in patients with AP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.